A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
Clinical trial NCT02061761 · COMPLETED
Trial details
- NCT number
- NCT02061761
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-13
- Primary completion
- 2022-02-16
- Enrollment
- 106
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.